Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Médecins Sans Frontières (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD) make up the endTB consortium conducting the groundbreaking study funded by Unitaid. Read Here.
top of page
Recent Posts
See AllThe Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
330
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
530
The monitoring and evaluation framework of the TB Action Plan for the WHO European Region 2023–2030 includes four new indicators reflecting consistent meaningful engagement of the communities and civi
540
bottom of page